Document Detail


Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.
MedLine Citation:
PMID:  23013138     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Multimarker quantitative real-time polymerase chain reaction (qRT-PCR) represents an effective method for detecting circulating tumour cells in the peripheral blood of patients with melanoma.
OBJECTIVES: To investigate whether the phenotype of circulating melanoma cells represents a useful indicator of disease stage, recurrence and treatment efficacy.
METHODS:   Peripheral blood was collected from 230 patients with melanoma and 152 healthy controls over a period of 3years and 9months. Clinical data and blood samples were collected from patients with primary melanoma (early stages, 0-II, n=154) and metastatic melanoma (late stages, III-IV, n=76). Each specimen was examined by qRT-PCR analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM.
RESULTS:  In total, 212 of the patients with melanoma (92%) expressed markers in their peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and were identified as statistically significant among patients who experienced disease recurrence within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients with recurrence (P=0·001 and P=0·031, respectively). For patients administered nonsurgical treatments, MCAM expression correlated with poor treatment outcome.
CONCLUSIONS: Circulating tumour cells were detectable at all stages of disease and long after surgical treatment, even when patients were considered disease free. Specifically, expression of ABCB5 and MLANA had significant prognostic value in inferring disease recurrence, while MCAM expression was associated with poor patient outcome after treatment, confirming multimarker qRT-PCR as a potential technique for monitoring disease status.
Authors:
A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman
Related Documents :
1343958 - Osteoradionecrosis of mandible in patients treated with definitive radiotherapy for car...
18258388 - High-dose-rate rotte "y" applicator brachytherapy for definitive treatment of medically...
19409728 - High-dose rate brachytherapy using inverse planning simulated annealing for locoregiona...
22844368 - Identification of a dna methylation marker that detects the presence of lymph node meta...
7882278 - Non-hodgkin's lymphoma of the sinonasal tract. a clinicopathologic and immunophenotypic...
23374558 - Radioembolisation with yttrium-90 microspheres: an effective treatment modality for unr...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-15
Journal Detail:
Title:  The British journal of dermatology     Volume:  168     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-06-07     Revised Date:  2014-09-09    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  85-92     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Case-Control Studies
Female
Humans
Male
Melanoma / blood,  pathology*,  therapy
Middle Aged
Neoplasm Recurrence, Local / pathology*
Neoplastic Cells, Circulating / pathology*
Phenotype
Real-Time Polymerase Chain Reaction
Skin Neoplasms / blood,  pathology*,  therapy
Treatment Outcome
Tumor Burden
Tumor Markers, Biological / blood*
Young Adult
Grant Support
ID/Acronym/Agency:
1R01CA138231/CA/NCI NIH HHS; 1R01CA158467/CA/NCI NIH HHS; 2P50CA093683/CA/NCI NIH HHS; 5R01CA113796/CA/NCI NIH HHS; P50 CA093683/CA/NCI NIH HHS; R01 CA113796/CA/NCI NIH HHS; R01 CA138231/CA/NCI NIH HHS; R01 CA158467/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological
Comments/Corrections
Comment In:
Br J Dermatol. 2013 Jan;168(1):3   [PMID:  23278557 ]
Br J Dermatol. 2014 Jul;171(1):190-1   [PMID:  24397844 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HIV prevalence and incidence among women at higher risk of infection in Addis Ababa, Ethiopia.
Next Document:  Hepatic resection for bilateral hepatolithiasis: a 20-year experience.